Key Highlights

  • Agios Pharmaceuticals shares fell approximately 13% in pre-market trading.
  • Phase 2 data for tebapivat in sickle cell disease showed hemoglobin responses of 29.4% to 47.1%, versus 33.3% for placebo.
  • The company decided to halt the sickle cell disease program due to a lack of significant differentiation.
  • Agios will now prioritize mitapivat, which holds FDA Priority Review with a PDUFA date of November 1, 2026.

Agios Pharmaceuticals (NASDAQ: AGIO) shares fell approximately 13% in pre-market trading after the company revealed Phase 2 data for tebapivat in sickle cell disease (SCD) and announced it would halt the program.

What Happened

The Phase 2 data showed hemoglobin responses between 29.4% and 47.1% in the treatment arms, compared with 33.3% for the placebo group.

Due to a lack of significant differentiation from placebo, the company has decided to halt the SCD program.

Agios will now prioritize mitapivat, which currently holds FDA Priority Review with an upcoming PDUFA date set for November 1, 2026.

Market Reaction

Shares fell approximately 13% in pre-market trading following the disclosure, reflecting investor disappointment over the discontinuation of the tebapivat SCD program.

Outlook

With the SCD program halted, Agios is now prioritizing mitapivat, which holds FDA Priority Review status ahead of its PDUFA date of November 1, 2026.

Why did Agios Pharmaceuticals halt its sickle cell disease program?

Phase 2 data showed hemoglobin responses of 29.4% to 47.1% versus 33.3% for placebo, a lack of significant differentiation that led the company to halt the program.

What is Agios now prioritizing?

The company will now prioritize mitapivat, which holds FDA Priority Review with a PDUFA date of November 1, 2026.

Why did Agios shares fall 13% pre-market?

Shares fell after the company disclosed the tebapivat SCD data and decision to halt that program.